Cantor Fitzgerald Predicts ESPR FY2024 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Cantor Fitzgerald issued their FY2024 earnings estimates for shares of Esperion Therapeutics in a research report issued on Tuesday, December 17th. Cantor Fitzgerald analyst K. Kluska expects that the biopharmaceutical company will post earnings per share of ($0.27) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $8.00 price target on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.27) per share.

A number of other analysts have also recently commented on ESPR. The Goldman Sachs Group initiated coverage on Esperion Therapeutics in a research report on Wednesday. They issued a “neutral” rating and a $4.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Thursday, December 12th. Needham & Company LLC restated a “buy” rating and set a $6.00 price target on shares of Esperion Therapeutics in a report on Friday, December 13th. Finally, StockNews.com lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $7.30.

Esperion Therapeutics Stock Performance

Shares of ESPR opened at $2.19 on Thursday. Esperion Therapeutics has a fifty-two week low of $1.58 and a fifty-two week high of $3.94. The firm’s 50-day simple moving average is $2.42 and its two-hundred day simple moving average is $2.22. The stock has a market cap of $431.51 million, a PE ratio of -3.42 and a beta of 1.01.

Institutional Trading of Esperion Therapeutics

Several institutional investors have recently added to or reduced their stakes in ESPR. Boomfish Wealth Group LLC raised its stake in shares of Esperion Therapeutics by 17.1% in the third quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company’s stock worth $58,000 after purchasing an additional 5,102 shares during the last quarter. Summit Financial LLC raised its position in Esperion Therapeutics by 26.4% in the 2nd quarter. Summit Financial LLC now owns 32,687 shares of the biopharmaceutical company’s stock worth $73,000 after buying an additional 6,823 shares during the last quarter. National Bank of Canada FI raised its position in Esperion Therapeutics by 115.9% in the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 10,225 shares during the last quarter. SG Americas Securities LLC lifted its stake in Esperion Therapeutics by 45.3% during the 2nd quarter. SG Americas Securities LLC now owns 37,414 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 11,658 shares during the period. Finally, BOKF NA purchased a new stake in shares of Esperion Therapeutics during the 2nd quarter valued at about $26,000. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.